78 related articles for article (PubMed ID: 9343029)
1. Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis.
Green CJ; Hadorn DC; Bassett K; Kazanjian A
Can J Cardiol; 1997 Sep; 13(9):811-5. PubMed ID: 9343029
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation in chronic nonvalvular atrial fibrillation: appraisal of two meta-analyses.
Blakely JA
Can J Cardiol; 1998 Jul; 14(7):945-8. PubMed ID: 9706280
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
4. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials.
Albers GW; Sherman DG; Gress DR; Paulseth JE; Petersen P
Ann Neurol; 1991 Oct; 30(4):511-8. PubMed ID: 1789680
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice.
Caro JJ; Flegel KM; Orejuela ME; Kelley HE; Speckman JL; Migliaccio-Walle K
CMAJ; 1999 Sep; 161(5):493-7. PubMed ID: 10497604
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulants for nonvalvular atrial fibrillation (NVAF)--drug review.
Cundiff DK
MedGenMed; 2003 Feb; 5(1):4. PubMed ID: 12827065
[TBL] [Abstract][Full Text] [Related]
7. Re: CJ Green, DC Hadorn, K Bassett, A Kazanjian. Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. 1997;13:811-5.
Laupacis A
Can J Cardiol; 1998 May; 14(5):659, 662; author reply 663, 665. PubMed ID: 9627518
[No Abstract] [Full Text] [Related]
8. Re: CJ Green, DC Hadorn, K Bassett, A Kazanjian, Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. 1997;13:811-5.
Mant MJ
Can J Cardiol; 1998 May; 14(5):663; author reply 663, 665. PubMed ID: 9627519
[No Abstract] [Full Text] [Related]
9. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
[TBL] [Abstract][Full Text] [Related]
10. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.
Garwood CL; Corbett TL
Ann Pharmacother; 2008 Apr; 42(4):523-32. PubMed ID: 18334606
[TBL] [Abstract][Full Text] [Related]
11. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic.
Abdelhafiz AH; Wheeldon NM
Clin Ther; 2004 Sep; 26(9):1470-8. PubMed ID: 15531009
[TBL] [Abstract][Full Text] [Related]
12. Preventing stroke in atrial fibrillation.
Wolf PA; Singer DE
Am Fam Physician; 1997 Dec; 56(9):2242-50. PubMed ID: 9402810
[TBL] [Abstract][Full Text] [Related]
13. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapy.
Partington SL; Abid S; Teo K; Oczkowski W; O'Donnell MJ
Thromb Res; 2007; 120(5):663-9. PubMed ID: 17434577
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic therapies for stroke prevention in atrial fibrillation.
Economides Muñoz C; Singh BN
Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
[TBL] [Abstract][Full Text] [Related]
15. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Halperin JL;
Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant treatment of patients with chronic atrial fibrillation in primary health care in Sweden--a retrospective study of incidence and quality in a registered population.
Nilsson GH; Björholt I; Krakau I
Fam Pract; 2004 Dec; 21(6):612-6. PubMed ID: 15465879
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant treatment in primary health care in Sweden - prevalence, incidence and treatment diagnosis: a retrospective study on electronic patient records in a registered population.
Nilsson GH; Björholt I; Johnsson H
BMC Fam Pract; 2003 Apr; 4():3. PubMed ID: 12675952
[TBL] [Abstract][Full Text] [Related]
18. Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records.
Nilsson GH; Björholt I
BMC Clin Pharmacol; 2004 Feb; 4():1. PubMed ID: 15028124
[TBL] [Abstract][Full Text] [Related]
19. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal.
Odén A; Fahlén M; Hart RG
Thromb Res; 2006; 117(5):493-9. PubMed ID: 16517250
[TBL] [Abstract][Full Text] [Related]
20. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
